Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: Data from the European randomized study of prostate cancer screening in Gothenburg, Sweden

Cancer

Volumn 116, Issue 11, 2010, Pages 2612-2620

  Vickers, Andrew J ^a   Cronin, Angel M ^a   Aus, Gunnar ^b   Pihl, Carl Gustav ^b   Becker, Charlotte ^c   Pettersson, Kim ^d   Scardino, Peter T ^a   Hugosson, Jonas ^b   Lilja, Hans ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Kallikreins; Molecular markers; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

KALLIKREIN RELATED PEPTIDASE 2; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SWEDEN;

AGED; BIOPSY; EARLY DETECTION OF CANCER; FORECASTING; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952800766     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25010     Document Type: Article

References (16)

1. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005;294:66-70. (Pubitemid 41002840)
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
3. Andriole GL, Grubb RL 3rd, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
4. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268-278. (Pubitemid 351430866)
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≥4.0 ng per milliliter. N Engl J Med. 2004;350: 2239-2246.
6. Vickers AJ, Cronin MS, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden [serial online]. BMC Med. 2008;6:19.
7. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534. (Pubitemid 43898816)
8. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer. 2004;100:1397-1405. (Pubitemid 38366842)
9. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors. 5th ed. New York: John Wiley & Sons; 1997.
10. Gleason DF; Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia, Pa: Lea & Febiger; 1977:171-198.
11. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565-574. (Pubitemid 44728772)
12. Durkan GC, Sheikh N, Johnson P, Hildreth AJ, Greene DR. Improving prostate cancer detection with an extended-core transrectal ultrasonography- guided prostate biopsy protocol. BJU Int. 2002;89:33-39. (Pubitemid 34117761)
13. Eskicorapci SY, Baydar DE, Akbal C, et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol. 2004;45:444-449. (Pubitemid 38376201)
14. Guichard G, Larre S, Gallina A, et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol. 2007;52: 430-435.
15. Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008;71:1016-1019.
16. Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol. 2008;54:274-290.